Format

Send to

Choose Destination
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1674-1692. doi: 10.1080/21691401.2019.1604535.

Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview.

Author information

1
a Department of Pharmaceutics, School of Pharmacy , China Pharmaceutical University , Nanjing , PR China.
2
b Department of Chemistry , Government College University , Faisalabad , Pakistan.
3
c Department of Pharmacy , Lahore College of Pharmaceutical Sciences , Lahore , Pakistan.
4
d College of Pharmacy , Gachon University, Hambakmoero , Yeonsu-gu, Incheon , Korea.
5
e Department of Pharmacogonsy , Faculty of Pharmaceutical Science, Government College University , Faisalabad , Pakistan.

Abstract

Cisplatin cis-(diammine)dichloridoplatinum(II) (CDDP) is the first platinum-based complex approved by the food and drug administration (FDA) of the United States (US). Cisplatin is the first line chemotherapeutic agent used alone or combined with radiations or other anti-cancer agents for a broad range of cancers such as lung, head and neck. Aroplatin™, Lipoplatin™ and SPI-077 are PEGylated liposome-based nano-formulations that are still under clinical trials. They have many limitations, for example, poor aqueous solubility, drug resistance and toxicities, which can be overcome by encapsulating the cisplatin in Nemours nanocarriers. The extensive literature from different electronic databases covers the different nano-delivery systems that are developed for cisplatin. This review critically emphasizes on the recent advancement, development, innovations and updated literature reported for different carrier systems for CDDP.

KEYWORDS:

Cisplatin; cancer; drug delivery system; inorganic carriers; nanotechnology; polymeric nanoparticles

PMID:
31066300
DOI:
10.1080/21691401.2019.1604535
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center